Literature DB >> 28585147

Optimal threshold of stimulated serum thyroglobulin level for 18F-FDG PET/CT imaging in patients with thyroid cancer.

Hong Chai1, Hu Zhang2, Yong-Li Yu1, Yun-Chao Gao3.   

Abstract

This study was to explore the optimal threshold of thyroid-stimulating hormone (TSH)-stimulated serum thyroglobulin (s-Tg) for patients who were to receive 18F-fluorodeoxyglucose (18F-FDG) PET/CT scan owing to clinical suspicion of differentiated thyroid cancer (DTC) recurrence but negative post-therapeutic 131I whole-body scan (131I-WBS). A total of 60 qualified patients underwent PET/CT scanning from October 2010 to July 2014. The receiver operating characteristic (ROC) curve analyses showed that s-Tg levels over 49 μg/L led to the highest diagnostic accuracy of PET/CT to detect recurrence, with a sensitivity of 89.5% and a specificity of 90.9%. Besides, bivariate correlation analysis showed positive correlation between s-Tg levels and the maximum standardized uptake values (SUVmax) of 18F-FDG in patients with positive PET/CT scanning, suggesting a significant influence of TSH both on Tg release and uptake of 18F-FDG. So, positive PET/CT imaging is expected when patients have negative 131I-WBS but s-Tg levels over 49 μg/L.

Entities:  

Keywords:  18F-fluorodeoxyglucose (18F-FDG); differentiated thyroid cancer (DTC); positron emission tomography/computed tomography (PET/CT); post-therapeutic 131I whole-body scan (131I-WBS); serum thyroglobulin (Tg); thyroid-stimulating hormone (TSH)

Mesh：

Substances：

Year:  2017        PMID： 28585147     DOI： 10.1007/s11596-017-1752-6

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN： 1672-0733


  15 in total

1.  Clinical value of 18-fluorine-fluorodihydroxyphenylalanine positron emission tomography/computed tomography in the follow-up of medullary thyroid carcinoma.

Authors:  Markus Luster; Wolfram Karges; Katrin Zeich; Sandra Pauls; Frederik A Verburg; Henning Dralle; Gerhard Glatting; Andreas K Buck; Christoph Solbach; Bernd Neumaier; Sven N Reske; Felix M Mottaghy
Journal:  Thyroid       Date:  2010-05       Impact factor: 6.568

2.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

3.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

4.  The role of TSH for 18F-FDG-PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis.

Authors:  Chao Ma; Jiawei Xie; Yanhui Lou; Yanyan Gao; Shuyao Zuo; Xufu Wang
Journal:  Eur J Endocrinol       Date:  2010-05-19       Impact factor: 6.664

5.  Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.

Authors:  F Moog; R Linke; N Manthey; R Tiling; P Knesewitsch; K Tatsch; K Hahn
Journal:  J Nucl Med       Date:  2000-12       Impact factor: 10.057

6.  Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.

Authors:  Gulin Ucmak Vural; Burcu Esen Akkas; Nur Ercakmak; Sandip Basu; Abass Alavi
Journal:  Clin Nucl Med       Date:  2012-10       Impact factor: 7.794

7.  Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.

Authors:  Sae Jung Na; Ie Ryung Yoo; Joo Hyun O; Chenghe Lin; Qiuyu Lin; Sung Hoon Kim; Soo Kyo Chung
Journal:  Ann Nucl Med       Date:  2011-10-05       Impact factor: 2.668

8.  Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer.

Authors:  Rosália P Padovani; Eyal Robenshtok; Matvey Brokhin; R Michael Tuttle
Journal:  Thyroid       Date:  2012-07-10       Impact factor: 6.568

9.  Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?

Authors:  Pierre Vera; Caroline Kuhn-Lansoy; Agathe Edet-Sanson; Sebastien Hapdey; Romain Modzelewski; Anne Hitzel; Joelle d'Anjou; Jean-Pierre Basuyau
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

10.  The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.

Authors:  Tomasz Trybek; Aldona Kowalska; Jacek Lesiak; Jacek Młynarczyk
Journal:  Nucl Med Rev Cent East Eur       Date:  2014
View more
  1 in total

1.  2-[18F]FDG PET in the Management of Radioiodine Refractory Differentiated Thyroid Cancer in the Era of Thyrosin-Kinases Inhibitors: A Real-Life Retrospective Study.

Authors:  Stefano Gay; Stefano Raffa; Anna De'Luca di Pietralata; Matteo Bauckneht; Lara Vera; Alberto Miceli; Manuela Albertelli; Silvia Morbelli; Massimo Giusti; Diego Ferone
Journal:  Diagnostics (Basel)       Date:  2022-02-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.